脂蛋白和痴呆的风险:来自三个队列研究的发现
Peter E Thomas1,2,3, Signe Vedel-Krogh1,2,3, Sune F Nielsen1,2
1Department of Clinical Biochemistry, Copenhagen University Hospital-Herlev and Gentofte, Borgmester Ib Juuls Vej 1, 2730 Herlev, Denmark.
European heart journal
|August 18, 2025
概括
高脂蛋白水平可能会增加血管痴呆的风险,但不会增加阿尔茨海默病的风险. 需要进一步的研究来证实脂蛋白和痴呆症之间的联系.
科学领域:
- 心血管科学 心血管科学
- 神经学 神经学
- 遗传学 是一个遗传学.
背景情况:
- 痴呆症和动脉样硬化心血管疾病 (ASCVD) 具有共同的危险因素.
- 高脂蛋白是已知的ASCVD风险因素,但其在痴呆症中的作用尚不清楚.
研究的目的:
- 调查脂蛋白水平与阿尔茨海默病 (AD) 和血管相关痴呆症 (VaD) 风险之间的关联.
- 在临床试验中评估脂蛋白降低疗法的影响.
主要方法:
- 分析了来自三个大队伍的539,478名个体的脂蛋白水平 (哥本哈根一般人口研究,哥本哈根城市心脏研究,英国生物银行).
- 长度随访长达30.2年,以记录AD和VaD诊断.
- 统计分析,考虑死亡的竞争风险.
主要成果:
- 在连续尺度上,脂蛋白水平与AD或VaD风险无关.
- 在英国生物库中,较高的脂蛋白水平与增加的VaD风险相关 (P = .01) 当考虑竞争风险时.
- 在哥本哈根研究中,LPA KIV-2重复 (表明较小的异形体大小) 与AD风险增加有关 (SHR 1.25).
结论:
- 低脂蛋白水平与痴呆症风险增加无关.
- 非常高的脂蛋白水平或小的异构体大小可能会增加痴呆症风险,需要进一步调查.
相关概念视频
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
Blood Studies for Cardiovascular System III: Serum Lipid Profile
293
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
293
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


